Research context
An early pilot phase 1 study investigated Melanotan II as a cyclic melanocortin analogue, recording pigmentation, pharmacodynamic observations and tolerability in a very small volunteer group.
Areas studied
- Melanocortin receptor pharmacology
- Pigmentation measurements
- Early human pharmacology
- Tolerability observations
Limitations and investigational status
The cited study involved only three volunteers and was designed as an early exploratory investigation. It cannot establish generalisable efficacy or safety.
References
For laboratory research use only. Information presented here summarises areas investigated in published research and is not intended as medical advice or as evidence of established effects in humans.